# EDGAR Filing Document

**Accession Number:** 0001826457
**File Stem:** 0001193125-26-267465
**Filing Date:** 2026-6
**Character Count:** 6473
**Document Hash:** 030dd51529069791cae4c96d7bd61508
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-267465.hdr.sgml**: 20260611

**ACCESSION NUMBER**: 0001193125-26-267465

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260611

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260611

**DATE AS OF CHANGE**: 20260611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Monte Rosa Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001826457
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40522
- **FILM NUMBER:** 261082941

**BUSINESS ADDRESS:**
- **STREET 1:** 321 HARRISON AVENUE
- **STREET 2:** SUITE 900
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118
- **BUSINESS PHONE:** 617-949-2643

**MAIL ADDRESS:**
- **STREET 1:** 321 HARRISON AVENUE
- **STREET 2:** SUITE 900
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02118

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

------

**FORM** 8-K

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 11, 2026

MONTE ROSA THERAPEUTICS, INC.

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| Delaware | 001-40522 | 84-3766197 |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

321 Harrison Avenue**,** Suite 900

Boston**,** MA 02118

**(Address of principal executive offices, including zip code)**

**(**617**)** 949-2643

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, $0.0001 par value per share | GLUE | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07. Submission of Matters to Vote of Security Holders**

On June 11, 2026, Monte Rosa Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 16, 2026, the record date for the Annual Meeting, there were 84,382,573 outstanding shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). The Company's stockholders voted on the following matters, which are described in detail in the Company's definitive proxy statement on Schedule 14A (the "Proxy Statement"): (i) to elect three directors, Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph.D., as Class II directors of the Company, each to serve for a three-year term expiring at the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, subject to their earlier death, resignation or removal and (ii) to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

<u>Proposal 1 - Election of Class II Director Nominees</u>

The stockholders of the Company elected Andrew Schiff, M.D., Chandra P. Leo, M.D. and Anthony Manning, Ph.D. as Class II directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until their successors have been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders' vote with respect to the election of the Class II directors were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Votes<br>For** | **Votes<br>Withheld** | **Broker<br>Non-Votes** |
| Andrew Schiff, M.D. | 71,409,008 | 741,197 | 3,128,885 |
| Chandra P. Leo, M.D. | 71,469,933 | 680,272 | 3,128,885 |
| Anthony Manning, Ph.D. | 56,995,916 | 15,154,289 | 3,128,885 |

---

<u>Proposal 2 - Ratification of Appointment of the Company's Independent Registered Public Accounting Firm</u>

The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders' vote with respect to such ratification were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes**<br>**For** | **Votes**<br>**Against** | <br>**Abstain** | **Broker**<br>**Non-Votes** |
| 75,171,524 | 57,950 | 49,616 | 0 |

---

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Monte Rosa Therapeutics, Inc. | Monte Rosa Therapeutics, Inc. |
| Date: June 11, 2026 | By: | /s/ Markus Warmuth |
|  |  | Markus Warmuth |
|  |  | President and Chief Executive Officer |

---

------